PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

Breast Cancer Research

Table 2 Types of PIK3CA mutations that were detected

Patient	Treatment category	Exon 9	Exon 20
1	FAC/FEC	E545K
2	FAC/FEC		H1047R
3	FAC/FEC		H1047R
4	FAC/FEC	E542K
5	FAC/FEC	E545K
6	FAC/FEC		H1047R
7	FAC/FEC	E545K
8	FAC/FEC	E545K
9	FAC/FEC		H1047R
10	FAC/FEC	E545K
11	FAC/FEC	E545K
12	FAC/FEC	E545K
13	TFAC/TFEC	Q546R
14	TFAC/TFEC		H1047T
15	TFAC/TFEC		H1047R
16	TFAC/TFEC		H1047R
17	TFAC/TFEC		H1047R
18	TFAC/TFEC	E545K
19	TFAC/TFEC	E542K
20	TFAC/TFEC	E542V
21	TFAC/TFEC		G1049R
22	TFAC/TFEC		H1047R
23	TFAC/TFEC		H1047R

Exon 1 mutations were also examined but no mutations were found. FAC, 5-fluoruracil, doxorubicin, and cyclophosphamide; FEC, 5-fluoruracil, epirubicin, and cyclophosphamide; PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide; TFAC, paclitaxel followed by 5-fluoruracil, doxorubicin, and cyclophosphamide; TFEC, paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide.

ISSN: 1465-542X